Newer Therapies Outperform Sorafenib in Real-World Analysis of Patients With HCC
Newer agents approved for frontline hepatocellular carcinoma, including lenvatinib, and atezolizumab/bevacizumab, yielded superior survival outcomes than sorafenib in a real-world setting.
Neoadjuvant Nivolumab/Ipilimumab Yields 95% Major Pathological Response Rate in dMMR Colon Cancer
Neoadjuvant immunotherapy starkly outperformed neoadjuvant chemotherapy in eliciting major pathological responses among patients with mismatch repair–deficient colon cancer, according to investigators.
Adagrasib Demonstrates CNS Activity in KRAS G12C+ NSCLC
The intracranial objective response rate was 32% among patients with KRAS G12C–mutant, non–small cell lung cancer who received adagrasib.
Acalabrutinib Decreases Toxicity Burden in Patients with CLL
Acalabrutinib was linked to a lower incidence of cardiovascular-related toxicities and overall toxicity burden compared with ibrutinib in patients with chronic lymphocytic leukemia.
pCR Rates Following Neoadjuvant Therapy Similar Between Black and White Women With Breast Cancer
Findings from a breast cancer analysis demonstrated that pathologic complete response and event-free survival rates were not significantly affected by patient’s race.
Anticipating the Future of Polycythemia Vera Treatment: Weighing Efficacy and Toxicity
An expert presenting at the Society of Hematology Oncology 2021 Annual Conference shared important updates in polycythemia vera (PV) treatment and weighed in on the direction of future treatment.
Myeloproliferative Neoplasms in Accelerated Phase Continue to Present as Treatment Challenge
Treating patients with myeloproliferative neoplasms in accelerated phase (MPN-AP) remains an ongoing challenge as there are still no standard therapeutic approaches, says an expert.
2 Novel Studies Set to Address Unanswered Questions in Liver Cancer
The aim of the two ongoing studies is to determine the optimal sequence of therapies in the second-or later-line treatment settings for patients with hepatocellular carcinoma.
Maintenance Olaparib Still Beneficial at 5-Year Mark
Maintenance olaparib showcased progression-free survival benefit in almost half of the patients with ovarian cancer vs 21% of those who received placebo, including consistent benefit in high- and low-risk patients.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512